VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
© 2022. The Author(s)..
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor complex (P-TEFb), a heterodimeric protein complex composed of cyclin dependent kinase 9 (CDK9) and cyclin T1, functions to regulate short half-life transcripts by phosphorylation of RNA Polymerase II (POLII). These transcripts are frequently dysregulated in hematologic malignancies; however, therapies targeting inhibition of P-TEFb have not yet achieved approval for cancer treatment. VIP152 kinome profiling revealed CDK9 as the main enzyme inhibited at 100 nM, with over a 10-fold increase in potency compared with other inhibitors currently in development for this target. VIP152 induced cell death in CLL cell lines and primary patient samples. Transcriptome analysis revealed inhibition of RNA degradation through the AU-Rich Element (ARE) dysregulation. Mechanistically, VIP152 inhibits the assembly of P-TEFb onto the transcription machinery and disturbs binding partners. Finally, immune competent mice engrafted with CLL-like cells of Eµ-MTCP1 over-expressing mice and treated with VIP152 demonstrated reduced disease burden and improvement in overall survival compared to vehicle-treated mice. These data suggest that VIP152 is a highly selective inhibitor of CDK9 that represents an attractive new therapy for CLL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Leukemia - 37(2023), 2 vom: 14. Feb., Seite 326-338 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sher, Steven [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.02.2023 Date Revised 30.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-022-01758-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34889841X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34889841X | ||
| 003 | DE-627 | ||
| 005 | 20231226041346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-022-01758-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM34889841X | ||
| 035 | |a (NLM)36376377 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sher, Steven |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2023 | ||
| 500 | |a Date Revised 30.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor complex (P-TEFb), a heterodimeric protein complex composed of cyclin dependent kinase 9 (CDK9) and cyclin T1, functions to regulate short half-life transcripts by phosphorylation of RNA Polymerase II (POLII). These transcripts are frequently dysregulated in hematologic malignancies; however, therapies targeting inhibition of P-TEFb have not yet achieved approval for cancer treatment. VIP152 kinome profiling revealed CDK9 as the main enzyme inhibited at 100 nM, with over a 10-fold increase in potency compared with other inhibitors currently in development for this target. VIP152 induced cell death in CLL cell lines and primary patient samples. Transcriptome analysis revealed inhibition of RNA degradation through the AU-Rich Element (ARE) dysregulation. Mechanistically, VIP152 inhibits the assembly of P-TEFb onto the transcription machinery and disturbs binding partners. Finally, immune competent mice engrafted with CLL-like cells of Eµ-MTCP1 over-expressing mice and treated with VIP152 demonstrated reduced disease burden and improvement in overall survival compared to vehicle-treated mice. These data suggest that VIP152 is a highly selective inhibitor of CDK9 that represents an attractive new therapy for CLL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Positive Transcriptional Elongation Factor B |2 NLM | |
| 650 | 7 | |a EC 2.7.11.- |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 9 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Cyclin T |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Whipp, Ethan |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Janek |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Pu |e verfasserin |4 aut | |
| 700 | 1 | |a Beaver, Larry |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Orwick, Shelley |e verfasserin |4 aut | |
| 700 | 1 | |a Ravikrishnan, Janani |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Brandi |e verfasserin |4 aut | |
| 700 | 1 | |a Perry, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Gregory, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Purcell, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Pearlly |e verfasserin |4 aut | |
| 700 | 1 | |a Alinari, Lapo |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Amy J |e verfasserin |4 aut | |
| 700 | 1 | |a Frigault, Melanie M |e verfasserin |4 aut | |
| 700 | 1 | |a Greer, Joy M |e verfasserin |4 aut | |
| 700 | 1 | |a Hamdy, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Xiaokui |e verfasserin |4 aut | |
| 700 | 1 | |a Sampath, Deepa |e verfasserin |4 aut | |
| 700 | 1 | |a Woyach, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Blachly, James |e verfasserin |4 aut | |
| 700 | 1 | |a Byrd, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Lapalombella, Rosa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 37(2023), 2 vom: 14. Feb., Seite 326-338 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:2 |g day:14 |g month:02 |g pages:326-338 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-022-01758-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 2 |b 14 |c 02 |h 326-338 | ||